Promising nerve pain drug trial for MGUS patients withdrawn before start

NCT ID NCT06046287

Terminated Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test if daratumumab could improve nerve damage (peripheral neuropathy) in people with a blood condition called MGUS. Participants would have received weekly injections for two months, then biweekly for four more months. However, the trial was withdrawn before enrolling anyone, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance peripheral nervous system disorder peripheral neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE PERIPHERAL NEUROPATHY

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center, Georgetown University

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.